Triplet therapies – the new standard of care for multiple myeloma: how to manage common toxicities

References

• Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341(21):1565–1571.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609–2617.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–1128.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–2520.
   PubMed Web of Science ®Google Scholar
• Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551–1560.
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207–1219.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Weiss BM, Plesner T, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016;128(1):37–44.
   PubMed Web of Science ®Google Scholar
• Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012;30(16):1953–1959.
   PubMed Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–631.
   PubMed Web of Science ®Google Scholar
• Durie BG, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519–527.
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, Bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311–1320.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142–152.
   PubMed Web of Science ®Google Scholar
• Moreau P, Masszi T, Grzasko N, et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016;374(17):1621–1634.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, Bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–766.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, Lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–1331.
   PubMed Web of Science ®Google Scholar
• Nooka AK, Kaufman JL, Behera M, et al. Efficacy and safety of triplet versus doublet salvage therapies among patients with Multiple Myeloma (MM) experiencing early relapse: meta-analysis of phase III Randomized Controlled Trials (RCTs). Blood. 2015;126(23):5344.
   Web of Science ®Google Scholar
• Stewart AK, Dimopoulos MA, Masszi T, et al. Health-related quality-of-life results from the open-label, randomized, Phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. J Clin Oncol. 2016;34(32):3921–3930.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Schlossman RL, Alsina M, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013;122(14):2331–2337.
   PubMed Web of Science ®Google Scholar
• Bringhen S, De Wit E, Dimopoulos MA. New agents in multiple myeloma: an examination of safety profiles. Clin Lymphoma Myeloma Leuk. 2017;17(7):391–407 e395.
   PubMed Web of Science ®Google Scholar
• McCullough KB, Hobbs MA, Abeykoon JP, et al. Common adverse effects of novel therapies for Multiple Myeloma (MM) and their management strategies. Curr Hematol Malig Rep. 2018;13(2):114–124.
   PubMed Web of Science ®Google Scholar
• Delforge M, Ludwig H. How I manage the toxicities of myeloma drugs. Blood. 2017;129(17):2359–2367.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Vij R, Noga SJ, et al. Treating multiple myeloma patients with oral therapies. Clin Lymphoma Myeloma Leuk. 2017;17(5):243–251.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Delforge M, Beksac M, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2012;26(4):595–608.
   PubMed Web of Science ®Google Scholar
• NCCN guidelines. Version 2.2018. [cited 2018 May 3].
   Google Scholar
• O’Donnell E, Laubach J, Yee AJ, et al. Final results of a phase 2 study of modified lenalidomide, Bortezomib, and Dexamethasone (RVD lite) in transplant-ineligible multiple myeloma. Blood. 2017;130(Suppl 1):3126.
   Google Scholar
• Kumar S, Berdeja JG, Niesvizky R, et al. Long-term ixazomib maintenance is tolerable and improves depth of response following ixazomib-lenalidomide-dexamethasone induction in Patients (Pts) with previously untreated Multiple Myeloma (MM): phase 2 Study Results. Blood. 2014;124(21):82.
   Google Scholar
• Kumar SK, Berdeja JG, Niesvizky R, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. The Lancet Oncology. 2014;15(13):1503–1512.
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120(9):1801–1809.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Roussou M, Gavriatopoulou M, et al. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. Am J Hematol. 2016;91(5):499–502.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Sonneveld P, Leung N, et al. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016;34(13):1544–1557.
   PubMed Web of Science ®Google Scholar
• Moreau P, Hulin C, Macro M, et al. Bortezomib, Thalidomide and Dexamethasone (VTD) Is Superior to Bortezomib, Cyclophosphamide and Dexamethasone (VCD) prior to autologous stem cell transplantation for patients with de novo multiple myeloma. results of the prospective IFM 2013-04 Trial. Blood. 2015;126(23):393.
   Web of Science ®Google Scholar
• Mai EK, Bertsch U, Durig J, et al. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia. 2015;29(8):1721–1729.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Grosicki S, Jedrzejczak WW, et al. Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible. Blood. 2015;126(23):26.
   PubMed Web of Science ®Google Scholar
• Kumar S, Moreau P, Hari P, et al. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. Br J Haematol. 2017;178(4):571–582.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Siegel D, Ludwig H, et al. Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): final Analysis from the Randomized Phase 3 Aspire Trial. Blood. 2017;130(Suppl 1):743.
   Google Scholar
• Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017;130(8):974–981.
   PubMed Web of Science ®Google Scholar
• Shah JJ, Stadtmauer EA, Abonour R, et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015;126(20):2284–2290.
   PubMed Web of Science ®Google Scholar
• Rosenbaum CA, Stephens LA, Kukreti V, et al. Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): A Multiple Myeloma Research Consortium multicenter study. J Clin Oncol. 2016;34.
   Web of Science ®Google Scholar
• Krishnan A, Kapoor P, Palmer JM, et al. Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. Leukemia. 2017.
   Web of Science ®Google Scholar
• Voorhees PM, Mulkey F, Hassoun H, et al. Alliance A061202. a Phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor based therapy: phase I results. Blood. 2015;126(23):375.
   Google Scholar
• Richardson PR, Beksac AO, Liberati M. Pomalidomide (POM), bortezomib, and low‐dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): phase 3 OPTIMISMM trial. J Clin Oncol. 2018;36.
   Web of Science ®Google Scholar
• Paludo J, Mikhael JR, LaPlant BR, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood. 2017;130(10):1198–1204.
   PubMed Web of Science ®Google Scholar
• Crawford J, Caserta C, Roila F, Group EGW. Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol. 2010;21(Suppl 5):v248–251.
   PubMedGoogle Scholar
• Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33(28):3199–3212.
   PubMed Web of Science ®Google Scholar
• Annibali O, Napolitano M, Avvisati G, et al. Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: critical review of the literature. Crit Rev Oncol Hematol. 2018;124:41–50.
   PubMedGoogle Scholar
• Kyprolis ^TM carfilzomib for injection. 2018 Amgen Inc. Available from: http://www.kyprolis-hcp.com/
   Google Scholar
• Darzalex^TM (daratumumab) injection for intravenous infusion 100mg/5ml, 400mg/20ml. Janssen Biotech, Inc. 2018. Available from: https://www.darzalex.com/
   Google Scholar
• American Society of Clinical Oncology 2017. [cited 2018 May 5]. Available from: www.asco.org/supportive-care-guidelines.
   Google Scholar
• Basser RL, Underhill C, Davis I, et al. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer. J Clin Oncol. 2000;18(15):2852–2861.
   PubMed Web of Science ®Google Scholar
• Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med. 1997;336(6):404–409.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Hamlin PA, Gabrilove J, et al. Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann Oncol. 2007;18(11):1842–1850.
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 2000;132(5):364–368.
   PubMed Web of Science ®Google Scholar
• Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology (Williston Park). 2015;29(4):282–294.
   PubMed Web of Science ®Google Scholar
• Rizzo JD, Brouwers M, Hurley P, et al. American society of clinical oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol. 2010;28(33):4996–5010.
   PubMed Web of Science ®Google Scholar
• Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085–2098.
   PubMed Web of Science ®Google Scholar
• Oostendorp M. Lammerts van Bueren JJ, Doshi P et al. When Blood Transfusion Medicine Becomes Complicated Due to Interference by Monoclonal Antibody Therapy. Transfusion. 2015;55(6 Pt 2):1555–1562.
   Google Scholar
• Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015;55(6 Pt 2):1545–1554.
   PubMed Web of Science ®Google Scholar
• Moreau P, van de Donk NW, San Miguel J, et al. Practical Considerations for the use of daratumumab, a novel CD38 monoclonal antibody, in myeloma. Drugs. 2016;76(8):853–867.
   PubMed Web of Science ®Google Scholar
• Blimark C, Holmberg E, Mellqvist UH, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107–113.
   PubMed Web of Science ®Google Scholar
• Robertson JD, Nagesh K, Jowitt SN, et al. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer. 2000;82(7):1261–1265.
   PubMed Web of Science ®Google Scholar
• Drayson MT, Bowcock S, Planche T, et al. Tackling Early Morbidity and Mortality in Myeloma (TEAMM): assessing the benefit of antibiotic prophylaxis and its effect on healthcare associated infections in 977 patients. Blood. 2017;130(Suppl 1):903.
   PubMedGoogle Scholar
• Chanan-Khan A, Sonneveld P, Schuster MW, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008;26(29):4784–4790.
   PubMed Web of Science ®Google Scholar
• Empliciti TM (elotuzumab) for injection for intravenous use 300mg & 400mg vials. 2018 Bristol-Myers Squibb Company. Available from: https://www.emplicitihcp.com.
   Google Scholar
• Boyle EM, Fouquet G, Manier S, et al. Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis. Expert Rev Hematol. 2012;5(6):617–626. quiz 627.
   PubMed Web of Science ®Google Scholar
• Leleu X. Thrombosis in myeloma treated with IMiDs. Thromb Res. 2012;130(Suppl 1):S63–65.
   PubMedGoogle Scholar
• Leebeek FW. Update of thrombosis in multiple myeloma. Thromb Res. 2016;140(Suppl 1):S76–80.
   PubMedGoogle Scholar
• Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11(1):29–37.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414–423.
   PubMed Web of Science ®Google Scholar
• Pegourie BPG, Karlin L. Evaluation of an oral direct anti-Xa anticoagulant, apixaban, for the prevention of venous thromboembolism in patients with myeloma treated with IMiD compounds: a pilot study (MYELAXAT). J Clin Oncol. 2017;35(15_suppl):8019.
   PubMedGoogle Scholar
• Roussel M, Lauwers-Cances V, Robillard N, et al. Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: primary Results of the Intergroupe Francophone Du MyéLome (IFM) Krd Phase II Study. Blood. 2016;128(22):1142.
   Web of Science ®Google Scholar
• Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146–153.
   PubMed Web of Science ®Google Scholar
• Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615–624.
   PubMed Web of Science ®Google Scholar
• Young A, Marshall A, Thirlwall J, et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the select-D™ pilot trial. Blood. 2017;130(Suppl 1):625.
   PubMedGoogle Scholar
• Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018;36(20):2017–2023.
   PubMed Web of Science ®Google Scholar
• Pawlyn C, Khan MS, Muls A, et al. Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. Blood. 2014;124(15):2467–2468.
   PubMed Web of Science ®Google Scholar
• Faiman B. Diarrhea in multiple myeloma: a review of the literature. Clin J Oncol Nurs. 2016;20(4):E100–105.
   PubMed Web of Science ®Google Scholar
• Kamm MA, Mueller-Lissner S, Wald A, et al. Oral bisacodyl is effective and well-tolerated in patients with chronic constipation. Clin Gastroenterol Hepatol. 2011;9(7):577–583.
   PubMed Web of Science ®Google Scholar
• Passmore AP, Davies KW, Flanagan PG, et al. A comparison of Agiolax and lactulose in elderly patients with chronic constipation. Pharmacology. 1993;47(Suppl 1):249–252.
   PubMed Web of Science ®Google Scholar
• Accardi F, Toscani D, Costa F, et al. The proteasome and myeloma-associated bone disease. Calcif Tissue Int. 2018;102(2):210–226.
   PubMed Web of Science ®Google Scholar
• Haidl F, Plesner T, Lund T. Treatment with bortezomib in multiple myeloma is associated with only a transient and brief increase of bone specific alkaline phosphatase. Leuk Res. 2012;36(10):1296–1299.
   PubMed Web of Science ®Google Scholar
• Zangari M, Esseltine D, Cavallo F, et al. Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. Am J Hematol. 2007;82(9):831–833.
   PubMed Web of Science ®Google Scholar
• Tinsley SM, Kurtin SE, Ridgeway JA. Practical management of lenalidomide-related rash. Clin Lymphoma Myeloma Leuk. 2015;15(Suppl):S64–69.
   PubMed Web of Science ®Google Scholar
• Villalon-Gomez JM. Pityriasis Rosea: diagnosis and treatment. Am Fam Physician. 2018;97(1):38–44.
   PubMed Web of Science ®Google Scholar
• Imbesi S, Allegra A, Calapai G, et al. Cutaneous adverse reactions to lenalidomide. Allergol Immunopathol (Madr). 2015;43(1):88–91.
   PubMed Web of Science ®Google Scholar
• Shaaban H, Layne T, Guron G. A case of DRESS (drug reaction with eosinophilia and systemic symptoms) with acute interstitial nephritis secondary to lenalidomide. J Oncol Pharm Pract. 2014;20(4):302–304.
   PubMed Web of Science ®Google Scholar
• Shanbhag A, Pritchard ER, Chatterjee K, et al. Highly probable drug reaction with eosinophilia and systemic symptoms syndrome associated with lenalidomide. Hosp Pharm. 2017;52(6):408–411.
   PubMedGoogle Scholar
• Wasch R, Jakob T, Technau K, et al. Stevens-Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation. Ann Hematol. 2012;91(2):287–289.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma. 2010;51(7):1178–1187.
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Laubach J, Anderson KC, et al. Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy. Blood. 2013;121(5):858.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Mateos MV, Richardson PG, et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol. 2011;86(1):23–31.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144(6):895–903.
   PubMed Web of Science ®Google Scholar
• Ale A, Bruna J, Navarro X, et al. Neurotoxicity induced by antineoplastic proteasome inhibitors. Neurotoxicology. 2014;43:28–35.
   PubMedGoogle Scholar
• Merz M, Salwender H, Haenel M, et al. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. Haematologica. 2015;100(7):964–969.
   PubMed Web of Science ®Google Scholar
• Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431–440.
   PubMed Web of Science ®Google Scholar
• Delforge M, Blade J, Dimopoulos MA, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol. 2010;11(11):1086–1095.
   PubMed Web of Science ®Google Scholar
• Bringhen S, D’Agostino M, De Paoli L, et al. Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. Leukemia. 2018;32(4):979–985.
   PubMed Web of Science ®Google Scholar
• Bringhen S, Petrucci MT, Larocca A, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014;124(1):63–69.
   PubMed Web of Science ®Google Scholar
• Jongen JL, Broijl A, Sonneveld P. Chemotherapy-induced peripheral neuropathies in hematological malignancies. J Neurooncol. 2015;121(2):229–237.
   PubMed Web of Science ®Google Scholar
• Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906–917.
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–173.
   PubMed Web of Science ®Google Scholar
• Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98(11):1753–1761.
   PubMed Web of Science ®Google Scholar
• Revlimid^TM (lenalidomide) capsules 25, 5, 10, 15, 20, 25mg. 2017 Celgene Corporation. Available from: https://www.revlimid.com.
   Google Scholar
• Pomalyst^TM (pomalidomide) capsules 1 2 3 4mg. 2018 Celgene Corporation. Available from: https://www.pomalyst.com.
   Google Scholar
• Grandin EW, Ky B, Cornell RF, et al. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. J Card Fail. 2015;21(2):138–144.
   PubMed Web of Science ®Google Scholar
• Chen-Scarabelli C, Corsetti G, Pasini E, et al. Spasmogenic effects of the proteasome inhibitor carfilzomib on coronary resistance, vascular tone and reactivity. EBioMedicine. 2017;21:206–212.
   PubMedGoogle Scholar
• Stangl K, Stangl V. The ubiquitin-proteasome pathway and endothelial (dys)function. Cardiovasc Res. 2010;85(2):281–290.
   PubMed Web of Science ®Google Scholar
• Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8(1):30–41.
   PubMed Web of Science ®Google Scholar
• Chari A, Hajje D. Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring. BMC Cancer. 2014;14(915).
   PubMedGoogle Scholar
• Danhof S, Schreder M, Rasche L, et al. ‘Real-life’ experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors. Eur J Haematol. 2016;97(1):25–32.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Roussou M, Gavriatopoulou M, et al. Cardiac and renal complications of carfilzomib in patients with multiple myeloma. Blood Adv. 2017;1(7):449–454.
   PubMed Web of Science ®Google Scholar
• Russell SD, Lyon A, Lenihan DJ, et al. Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial. Blood. 2015;126(23):4250.
   Web of Science ®Google Scholar
• Rosenthal A, Luthi J, Belohlavek M, et al. Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?. Blood Cancer J. 2016;6(e384).
   Google Scholar
• Lendvai N, Tsakos I, Devlin SM, et al. Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity. Leuk Lymphoma. 2018;59(8):1981–1985.
   Web of Science ®Google Scholar
• Harvey RD. Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib. Clin Pharmacol. 2014;6:87–96.
   PubMedGoogle Scholar
• Siegel DS. From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma. Ther Adv Hematol. 2013;4(6):354–365.
   PubMedGoogle Scholar
• Mikhael J. Management of carfilzomib-associated cardiac adverse events. Clin Lymphoma Myeloma Leuk. 2016;16(5):241–245.
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, DeCara JM, Mezzi K. Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies. Hematology. 2017;22(10):585–591.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27–38.
   PubMed Web of Science ®Google Scholar
• San Miguel J, Blade J, Boccadoro M, et al. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist. 2006;11(1):51–61.
   PubMed Web of Science ®Google Scholar
• Qaqish I, Schlam IM, Chakkera HA, et al. Carfilzomib: A cause of drug associated thrombotic microangiopathy. Transfus Apher Sci. 2016;54(3):401–404.
   PubMed Web of Science ®Google Scholar
• Sullivan MR, Danilov AV, Lansigan F, et al. Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange. J Clin Apher. 2015;30(5):308–310.
   PubMed Web of Science ®Google Scholar
• Cheungpasitporn W, Leung N, Rajkumar SV, et al. Bortezomib-induced acute interstitial nephritis. Nephrol Dial Transplant. 2015;30(7):1225–1229.
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Huff CA, Holanda DG, McDevitt MA, Fine DM. Lenalidomide-induced acute interstitial nephritis. Oncologist. 2010;15(9):961–964.
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Weiss B, Usmani S, et al. Management of infusion-related reactions following daratumumab monotherapy in patients with at least 3 lines of prior therapy or double refractory multiple myeloma (mm): 54767414mmy2002 (sirius). Blood. 2015;126(23):1829.
   Web of Science ®Google Scholar
• Chari A, Mark TM, Krishnan A, et al. Use of Montelukast to reduce infusion reactions in an early access treatment protocol of daratumumab in united states patients with relapsed or refractory multiple myeloma. Blood. 2016;128(22):2142.
   Web of Science ®Google Scholar
• Chari A, Nahi H, Mateos M-V, et al. Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): pavo, an open-label, multicenter, dose escalation phase 1b study. Blood. 2017;130(Suppl 1):838.
   Google Scholar
• Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120(14):2817–2825.
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Costa LJ, Reeves B, et al. Interim Safety Analysis of a Phase 2 Randomized Study of Daratumumab (DARA), Lenalidomide (R), Bortezomib (V), and Dexamethasone (d; DARA-Rvd) . Rvd in Patients (Pts) with Newly Diagnosed Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)Vs. Blood. 1879-1879;130(Suppl 1):2017.
   Google Scholar
• Chari A, Usmani SZ, Krishnan A, et al. Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): updated Results from an Open-Label, Phase 1b Study. Blood. 2017;130(Suppl 1):3110.
   Google Scholar
• Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518–528.
   PubMed Web of Science ®Google Scholar
• Vogl DT, Dingli D, Cornell RF, et al. Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36(9):859–866.
   PubMed Web of Science ®Google Scholar
• Kumar S, Vij R, Kaufman JL, et al. Venetoclax monotherapy for relapsed/refractory multiple myeloma: safety and efficacy results from a phase I Study. Blood. 2016;128(22):488.
   PubMedGoogle Scholar
• Moreau P, Chanan-Khan AA, Roberts AW, et al. Venetoclax Combined with Bortezomib and dexamethasone for patients with relapsed/refractory multiple Myeloma. Blood. 2016;128(22):975.
   Web of Science ®Google Scholar
• Cohen AD, Popat R, Trudel S, et al. First in Human Study with GSK2857916, an antibody drug conjugated to microtubule-disrupting agent directed against b-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): results from Study BMA117159 Part 1 Dose Escalation. Blood. 2016;128(22):1148.
   Web of Science ®Google Scholar
• San Miguel J, Mateos M-V, Shah JJ, et al. Pembrolizumab in Combination with Lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): keynote-023. Blood. 2015;126(23):505.
   Google Scholar
• Badros AZ, Kocoglu MH, Ma N, et al. A phase II study of anti PD-1 antibody pembrolizumab, pomalidomide and dexamethasone in patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 2015;126(23):506.
   Web of Science ®Google Scholar
• Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3(1):28–35.
   PubMed Web of Science ®Google Scholar